A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
RecruitingThis is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Alzheimer's Disease. The primary objective of the study is to evaluate relapse prevention in subjects with psychosis associated with Alzheimer's Disease treated with KarXT compared to placebo. The secondary objectives of the study are to evaluate the time from randomization to discontinuation for any reason or relapse and safety and tolerability in subjects with psychosis associated with Alzheimer's Disease treated with KarXT compared to placebo.
PhasePhase 3
TypeInterventional
Age55 Years – 90 Years
WhereHomewood, Alabama, United States + 128 more
SponsorKaruna Therapeutics, Inc., a Bristol Myers Squibb company
▾Tap for detailsClick for full details — eligibility, all locations, contacts ACP-204 in Adults With Alzheimer's Disease Psychosis
RecruitingThis is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies in patients with ADP * Substudy 1 (Phase 2) will evaluate efficacy and dose response of ACP-204 30 and 60 mg vs placebo. This substudy will be initiated first. * Substudies 2A and 2B (both: Phase 3) will be confirmatory studies of either both doses (ACP-204 30 and 60 mg, respectively) or a single dose from Part 1 vs placebo. Substudies 2A and 2B will be performed independently of each other and will commence after enrollment of Part 1. All 3 substudies will be analyzed independently of each other. Each substudy individually will consist of a screening period (up to 49 days); a double-blind treatment period (6 weeks); a safety follow-up period (30 days) for patients not rolling over into an open-label extension study; and vital status follow-up (for patients who terminated their substudy early).
PhasePhase 2 / Phase 3
TypeInterventional
Age55 Years – 95 Years
WhereChandler, Arizona, United States + 154 more
SponsorACADIA Pharmaceuticals Inc.
▾Tap for detailsClick for full details — eligibility, all locations, contacts Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
NCT06808984 · Agitation,
Alzheimer Disease RecruitingThis is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.
PhasePhase 2
TypeInterventional
Age55 Years – 90 Years
WhereHomewood, Alabama, United States + 76 more
SponsorCelgene
▾Tap for detailsClick for full details — eligibility, all locations, contacts Flutemetamol F 18 Injection Formulation Comparison
NCT07873463 · Cognitive Dysfunction
RecruitingVIZAMYL (flutemetamol F 18 injection) is a drug used during Positron Emission Tomography (PET) brain scans. It helps doctors detect the presence of amyloid protein, which is associated with Alzheimer's disease and other conditions affecting memory or thinking. A new formulation of this drug, called GE-287, has been developed. This new formulation may offer advantages for patient tolerability and can be produced more reliably and efficiently. The aim of the study is to determine whether the new formulation works as well as the current one in identifying amyloid in the brain, how it distributes in the body, and whether it is safe for use. The study will measure how much of the study drug goes to different organs (including the brain, heart, liver, and kidneys) and monitor for any side effects.
PhasePhase 2
TypeInterventional
Age50 Years – 110 Years
WhereAventura, Florida, United States + 5 more
SponsorGE Healthcare
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595 · Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies
RecruitingThe main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily activities) decline. For each participant, the study will last one and a half years.
PhasePhase 2
TypeInterventional
Age55 Years – 85 Years
WhereChandler, Arizona, United States + 71 more
SponsorEli Lilly and Company
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
RecruitingML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated with Alzheimer's Disease Psychosis (ADP). The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo for the treatment of hallucinations and delusions associated with ADP as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score.
PhasePhase 2
TypeInterventional
Age55 Years – 90 Years
WherePhoenix, Arizona, United States + 68 more
SponsorMapLight Therapeutics
▾Tap for detailsClick for full details — eligibility, all locations, contacts Late Onset Alzheimer's Disease
RecruitingThe goal of this study is to is to focus on the genetic influences on Alzheimer's Disease (AD) risk. The investigators are looking for families and/or individuals (affected or unaffected) of any ethic background (African American, Caucasian, and Hispanics) with a family history of AD and willing to participate.
Phase—
TypeObservational
Age55 Years
WhereWashington D.C., District of Columbia, United States + 11 more
SponsorColumbia University
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
RecruitingThe purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.
PhasePhase 3
TypeInterventional
Age55 Years – 90 Years
WhereChandler, Arizona, United States + 142 more
SponsorBristol-Myers Squibb
▾Tap for detailsClick for full details — eligibility, all locations, contacts Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
RecruitingThis is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026, CN012-0027 or CN012-0056. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026 study, 14-week CN012-0027 study or 14-week CN012-0056 study will be eligible to enroll in CN012-0028. The primary objective of the study is to assess the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer's Disease.
PhasePhase 3
TypeInterventional
Age55 Years – 90 Years
WhereHomewood, Alabama, United States + 431 more
SponsorKaruna Therapeutics, Inc., a Bristol Myers Squibb company
▾Tap for detailsClick for full details — eligibility, all locations, contacts Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895 · Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis
RecruitingTransthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall apart. One way occurs as a person ages, where the normal TTR protein can fall apart and form amyloid that may no longer be sufficiently cleared by the body. This type of ATTR is known as wild-type ATTR (ATTRwt). The other way occurs when a person inherits a defective TTR gene that causes the TTR protein to spontaneously fall apart. This form of the disease is known as variant ATTR (ATTRv) and can be detected in adults by a genetic test of their TTR gene before they age. Amyloid build-up in the heart causes the heart wall to become thick and stiff and can result in heart failure and even death. Accumulation of TTR amyloid in the heart is known as transthyretin amyloid cardiomyopathy or ATTR-CM. Amyloid can also deposit in the nerve tissues leading to nerve problems. Accumulation of TTR in the nerves is known as transthyretin amyloid polyneuropathy or ATTR-PN. Acoramidis is an experimental drug designed to bind tightly to TTR in the blood and stabilize its structure, so it does not form the harmful amyloid plaques that can cause damage to organs. This study is intended to determine if treatment with acoramidis in participants with ATTRv who have not yet developed any symptoms of disease can prevent or delay the development of ATTR-CM or ATTR-PN disease. If adults with an inherited defective TTR gene are treated early before any of the symptoms of disease have developed, it may be possible to delay the onset or prevent the disease entirely.
PhasePhase 3
TypeInterventional
Age18 Years – 75 Years
WhereLa Jolla, California, United States + 103 more
SponsorEidos Therapeutics, a BridgeBio company
▾Tap for detailsClick for full details — eligibility, all locations, contacts Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy
NCT03657745 ·
Alzheimer Disease, Mild Cognitive Impairment, Dementia
RecruitingElectrical activity in the brain known as "gamma" brainwaves help connect and process information throughout the brain. These gamma waves are diminished in Alzheimer's disease. New research in Alzheimer's disease mouse models shows that exposure to light flickering at the rate of 40 flashes per second or 40Hz increased gamma brainwaves and led to clearing of beta amyloid plaques in the brain, a key abnormality in Alzheimer's disease. This project will test the ability of a novel iPad App (AlzLife https://www.alz.life/) that delivers light therapy at 40 Hz combined with cognitive therapy to improve cognition, function, and quality of life in Alzheimer's disease.
Phase—
TypeObservational
Age50 Years
WhereMiami, Florida, United States
SponsorAlzheimer's Light LLC
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
RecruitingThe primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.
PhasePhase 4
TypeInterventional
Age50 Years
WhereIrvine, California, United States + 25 more
SponsorAlpha Cognition, Inc
▾Tap for detailsClick for full details — eligibility, all locations, contacts Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
RecruitingThis study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
PhasePhase 3
TypeInterventional
Age50 Years – 90 Years
WhereBirmingham, Alabama, United States + 235 more
SponsorHoffmann-La Roche
▾Tap for detailsClick for full details — eligibility, all locations, contacts Longitudinal Cognitive Assessment by BoCA
NCT04114994 ·
Alzheimer Disease, Mild Cognitive Impairment, Vascular Dementia
RecruitingThe Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects. BoCA was developed to evaluate the effects of treatment in longitudinal clinical trials and available gratis to individuals and professionals.
Phase—
TypeObservational
Age50 Years
WhereMiami, Florida, United States
SponsorAlzheimer's Light LLC
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
NCT07602582 ·
Alzheimer Disease, Dementia, Plaque, Amyloid
RecruitingThe main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.
PhasePhase 3
TypeInterventional
Age55 Years
WherePhoenix, Arizona, United States + 61 more
SponsorEli Lilly and Company
▾Tap for detailsClick for full details — eligibility, all locations, contacts Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
RecruitingBio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective. Digital biomarkers and blood-based biomarkers will be tested to determine whether a meaningful relationship exists between biomarkers alone or in combination with tau or amyloid brain pathology identified through PET images.
Phase—
TypeObservational
Age60 Years – 90 Years
WhereAtlantis, Florida, United States + 25 more
SponsorGAP Innovations, PBC
▾Tap for detailsClick for full details — eligibility, all locations, contacts ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
RecruitingThe purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).
PhaseNA
TypeInterventional
Age50 Years – 85 Years
WhereDelray Beach, Florida, United States + 9 more
SponsorInSightec
▾Tap for detailsClick for full details — eligibility, all locations, contacts Personalized Obstructive Sleep Apnea Treatment and Effects on Alzheimer's Disease Biomarkers and Cognition Among Blacks
NCT06089161 · Sleep Apnea
RecruitingThe purpose of this research is to see how effective the Personalized obstructive sleep apnea (OSA) Treatment Adherence Model called PRAISE is in helping the patient stick to the physician recommended OSA treatment plan Positive Airway Pressure (PAP).
PhaseNA
TypeInterventional
Age55 Years – 85 Years
WhereMiami, Florida, United States
SponsorUniversity of Miami
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
NCT06651567 · Agitation Associated With Alzheimer's Dementia
RecruitingThis is a multicenter, randomized, double-blind, placebo-controlled, flexible-dose study of the efficacy, safety, and tolerability of ITI-1284 in patients with agitation associated with Alzheimer's dementia.
PhasePhase 2
TypeInterventional
Age55 Years
WhereAnaheim, California, United States + 70 more
SponsorIntra-Cellular Therapies, Inc.
▾Tap for detailsClick for full details — eligibility, all locations, contacts [18F]PI-2620 Phase 3 Histopathological Study
RecruitingThis study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with \[18F\]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.
PhasePhase 3
TypeInterventional
Age50 Years
WherePhoenix, Arizona, United States + 24 more
SponsorLantheus Biosciences Ltd.
▾Tap for detailsClick for full details — eligibility, all locations, contacts